These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 20028728)

  • 1. Clinical relevance of C-reactive protein in ankylosing spondylitis and evaluation of the NSAIDs/coxibs' treatment effect on C-reactive protein.
    Benhamou M; Gossec L; Dougados M
    Rheumatology (Oxford); 2010 Mar; 49(3):536-41. PubMed ID: 20028728
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Erythrocyte sedimentation rate, C-reactive protein level, and serum amyloid a protein for patient selection and monitoring of anti-tumor necrosis factor treatment in ankylosing spondylitis.
    de Vries MK; van Eijk IC; van der Horst-Bruinsma IE; Peters MJ; Nurmohamed MT; Dijkmans BA; Hazenberg BP; Wolbink GJ
    Arthritis Rheum; 2009 Nov; 61(11):1484-90. PubMed ID: 19877087
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical relevance of C-reactive protein in axial involvement of ankylosing spondylitis.
    Dougados M; Gueguen A; Nakache JP; Velicitat P; Zeidler H; Veys E; Calin A
    J Rheumatol; 1999 Apr; 26(4):971-4. PubMed ID: 10229430
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost effectiveness of etoricoxib versus celecoxib and non-selective NSAIDS in the treatment of ankylosing spondylitis.
    Jansen JP; Gaugris S; Choy EH; Ostor A; Nash JT; Stam W
    Pharmacoeconomics; 2010; 28(4):323-44. PubMed ID: 20222755
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of celecoxib, a cyclooxygenase 2-specific inhibitor, in the treatment of ankylosing spondylitis: a six-week controlled study with comparison against placebo and against a conventional nonsteroidal antiinflammatory drug.
    Dougados M; Béhier JM; Jolchine I; Calin A; van der Heijde D; Olivieri I; Zeidler H; Herman H
    Arthritis Rheum; 2001 Jan; 44(1):180-5. PubMed ID: 11212158
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of the efficacy of pamidronate in ankylosing spondylitis: an open prospective trial.
    Santra G; Sarkar RN; Phaujdar S; Banerjee S; Siddhanta S
    Singapore Med J; 2010 Nov; 51(11):883-7. PubMed ID: 21140116
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Effective also in Bechterew disease].
    MMW Fortschr Med; 2007 Jun; 149(25-26):46-7. PubMed ID: 17713052
    [No Abstract]   [Full Text] [Related]  

  • 8. Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial.
    Wanders A; Heijde Dv; Landewé R; Béhier JM; Calin A; Olivieri I; Zeidler H; Dougados M
    Arthritis Rheum; 2005 Jun; 52(6):1756-65. PubMed ID: 15934081
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Celecoxib compared with lansoprazole and naproxen to prevent gastrointestinal ulcer complications.
    Lai KC; Chu KM; Hui WM; Wong BC; Hu WH; Wong WM; Chan AO; Wong J; Lam SK
    Am J Med; 2005 Nov; 118(11):1271-8. PubMed ID: 16271912
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Bechterew disease--a consensus on diagnosis and treatment].
    Dagfinrud H; Heiberg MS; Bakland G; Skomsvoll J; Kvien TK
    Tidsskr Nor Laegeforen; 2007 Dec; 127(24):3209-12. PubMed ID: 18084362
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of two different dosages of celecoxib with diclofenac for the treatment of active ankylosing spondylitis: results of a 12-week randomised, double-blind, controlled study.
    Sieper J; Klopsch T; Richter M; Kapelle A; Rudwaleit M; Schwank S; Regourd E; May M
    Ann Rheum Dis; 2008 Mar; 67(3):323-9. PubMed ID: 17616556
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prospects for disease modification in ankylosing spondylitis: do nonsteroidal antiinflammatory drugs do more than treat symptoms?
    Ward MM
    Arthritis Rheum; 2005 Jun; 52(6):1634-6. PubMed ID: 15934065
    [No Abstract]   [Full Text] [Related]  

  • 13. Celecoxib approved for pain relief for AS.
    Health News; 2005 Nov; 11(11):2. PubMed ID: 16294424
    [No Abstract]   [Full Text] [Related]  

  • 14. Celecoxib is efficacious and well tolerated in treating signs and symptoms of ankylosing spondylitis.
    Barkhuizen A; Steinfeld S; Robbins J; West C; Coombs J; Zwillich S
    J Rheumatol; 2006 Sep; 33(9):1805-12. PubMed ID: 16960941
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of selective and non-selective non-steroid anti-inflammatory drugs on secondary hemostasis in healthy volunteers.
    Schjerning O; Larsen TB; Damkier P
    Thromb Res; 2009 Jun; 124(2):208-12. PubMed ID: 19269020
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Etoricoxib in ankylosing spondylitis: is there a role for active patients refractory to traditional NSAIDs?
    Gratacós J; Moreno Martínez-Losa M; Font P; Montilla C; Fernández-Espartero C; Linares LF; Brito E; Oliva JC; Collantes-Estevez E;
    Clin Exp Rheumatol; 2016; 34(1):94-9. PubMed ID: 26812050
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug testing. Massive trial of Celebrex seeks to settle safety concerns.
    Couzin J
    Science; 2005 Dec; 310(5756):1890-1. PubMed ID: 16373546
    [No Abstract]   [Full Text] [Related]  

  • 18. How to define remission in ankylosing spondylitis?
    Sieper J
    Ann Rheum Dis; 2012 Apr; 71 Suppl 2():i93-5. PubMed ID: 22460148
    [No Abstract]   [Full Text] [Related]  

  • 19. Can treatment with nonsteroidal anti-inflammatory drugs protect from dementia?
    Bregman N; Karni A; Korczyn AD
    Arch Neurol; 2009 Apr; 66(4):539-40; author reply 540. PubMed ID: 19364945
    [No Abstract]   [Full Text] [Related]  

  • 20. Genetic polymorphisms and the cardiovascular risk of non-steroidal anti-inflammatory drugs.
    St Germaine CG; Bogaty P; Boyer L; Hanley J; Engert JC; Brophy JM
    Am J Cardiol; 2010 Jun; 105(12):1740-5. PubMed ID: 20538124
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.